New perspectives on the biology of acute GVHD
暂无分享,去创建一个
D. Hanauer | S. Paczesny | S Paczesny | D Hanauer | Y Sun | P Reddy | P. Reddy | Y. Sun | Yaping Sun
[1] Billingham Re. The biology of graft-versus-host reactions. , 1966 .
[2] R. Billingham. The biology of graft-versus-host reactions. , 1966, Harvey lectures.
[3] J. Sprent,et al. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow , 1978, The Journal of experimental medicine.
[4] P. Vassalli,et al. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease , 1987, The Journal of experimental medicine.
[5] J. Ferrara,et al. Cytokine dysregulation and acute graft-versus-host disease. , 1992, Blood.
[6] D. Gilliland,et al. Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens. , 1993, Transplantation.
[7] H Hengartner,et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. , 1994, Science.
[8] P. Linsley,et al. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. , 1994, Blood.
[9] John S. Thompson,et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2- incompatible transplanted SCID mice , 1994 .
[10] M. Eckhaus,et al. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. , 1994, Blood.
[11] J. Ferrara,et al. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. , 1995, Journal of immunology.
[12] J. Ferrara,et al. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. , 1995, Blood.
[13] F Koning,et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. , 1995, Science.
[14] H. V. van Houwelingen,et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. , 1996, The New England journal of medicine.
[15] J. Ferrara,et al. Interferon-gamma suppresses T-cell proliferation to mitogen via the nitric oxide pathway during experimental acute graft-versus-host disease. , 1996, Blood.
[16] J. Crawford,et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. , 1997, Blood.
[17] R. Flavell,et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. , 1997, Journal of immunology.
[18] A. Nademanee,et al. Phase III Study Comparing Methotrexate and Tacrolimus ( Prograf , FK 506 ) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation , 1998 .
[19] M. Sykes,et al. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12. , 1998, The Journal of clinical investigation.
[20] J. Crawford,et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.
[21] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[22] J. Ferrara,et al. Graft-versus-host disease: the influence of type 1 and type 2 T cell cytokines. , 1998, Transfusion medicine reviews.
[23] J. Crawford,et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. , 1998, The Journal of clinical investigation.
[24] A. Nademanee,et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.
[25] D. Taub,et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. , 1998, The Journal of clinical investigation.
[26] M. Garcia-Ojeda,et al. Bone Marrow NK1.1− and NK1.1+ T Cells Reciprocally Regulate Acute Graft versus Host Disease , 1999, The Journal of experimental medicine.
[27] 直子 加藤,et al. Graft-Versus-host Disease , 1999 .
[28] K. Matsushima,et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. , 1999, The Journal of clinical investigation.
[29] M. Shlomchik,et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. , 1999, Science.
[30] G. Hill,et al. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.
[31] R. Bronson,et al. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. , 2000, The Journal of clinical investigation.
[32] R. Gress,et al. Th2 and Tc2 Cells in the Regulation of GVHD, GVL, and Graft Rejection: Considerations for the Allogeneic Transplantation Therapy of Leukemia and Lymphoma , 2000, Leukemia & lymphoma.
[33] F. P. Nestel,et al. Activation of macrophage cytostatic effector mechanisms during acute graft-versus-host disease: release of intracellular iron and nitric oxide-mediated cytostasis. , 2000, Blood.
[34] J. Peschon,et al. Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.
[35] R. Negrin,et al. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. , 2001, Blood.
[36] J. Ferrara,et al. Interleukin-18 Regulates Acute Graft-Versus-Host Disease by Enhancing Fas-mediated Donor T Cell Apoptosis , 2001, The Journal of experimental medicine.
[37] G. Schuler,et al. Ex Vivo Isolation and Characterization of Cd4+Cd25+ T Cells with Regulatory Properties from Human Blood , 2001, The Journal of experimental medicine.
[38] S. Chevret,et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA-identical sibling transplants. , 2001, Experimental hematology.
[39] A. Enk,et al. Identification and Functional Characterization of Human Cd4+Cd25+ T Cells with Regulatory Properties Isolated from Peripheral Blood , 2001, The Journal of experimental medicine.
[40] C. Perreault,et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease , 2001, Nature Medicine.
[41] R. Collins,et al. Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation. , 2001, Blood.
[42] C. Fathman,et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.
[43] D. Thiele,et al. TNF-TNFR2 Interactions Are Critical for the Development of Intestinal Graft-Versus-Host Disease in MHC Class II-Disparate (C57BL/6J→C57BL/6J × bm12)F1 Mice1 , 2002, The Journal of Immunology.
[44] B. Blazar,et al. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. , 2002, Blood.
[45] S. Burakoff,et al. Cytolytic pathways in haematopoietic stem-cell transplantation , 2002, Nature Reviews Immunology.
[46] G. Freeman,et al. The B7–CD28 superfamily , 2002, Nature Reviews Immunology.
[47] M. Sykes,et al. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells. , 2002, Blood.
[48] Eun Young Choi,et al. Immunodominance of H60 is caused by an abnormally high precursor T cell pool directed against its unique minor histocompatibility antigen peptide. , 2002, Immunity.
[49] J. Crawford,et al. T cells require TRAIL for optimal graft-versus-tumor activity , 2002, Nature Medicine.
[50] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[51] C. Fathman,et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.
[52] S. Clouthier,et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. , 2003, Experimental hematology.
[53] P. Reddy. Pathophysiology of acute graft‐versus‐host disease , 2003, Hematological oncology.
[54] Li Zhang,et al. Inhibition of Graft-Versus-Host Disease by Double-Negative Regulatory T Cells1 , 2003, The Journal of Immunology.
[55] 村田 誠. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion , 2003 .
[56] L. Appleman,et al. T cell anergy and costimulation , 2003, Immunological reviews.
[57] A. Sharpe,et al. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. , 2003, Blood.
[58] G. Núñez,et al. Cell death and immunity: NODs: intracellular proteins involved in inflammation and apoptosis , 2003, Nature Reviews Immunology.
[59] J. Ferrara,et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. , 2003, Blood.
[60] M. Shlomchik,et al. Memory CD4+ T cells do not induce graft-versus-host disease. , 2003, The Journal of clinical investigation.
[61] Stephen C. Jones,et al. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[62] A. Panoskaltsis-Mortari,et al. Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-γ-Dependent Mechanism1 , 2003, The Journal of Immunology.
[63] Irving L Weissman,et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease , 2004, Nature Medicine.
[64] J. Serody,et al. Differential Roles for CCR5 Expression on Donor T Cells during Graft-versus-Host Disease Based on Pretransplant Conditioning1 , 2004, The Journal of Immunology.
[65] M. Labopin,et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] T. Mak,et al. CD30/CD30 Ligand (CD153) Interaction Regulates CD4+ T Cell-Mediated Graft-versus-Host Disease1 , 2004, The Journal of Immunology.
[67] G. Rogler,et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. , 2004, Blood.
[68] J. Serody,et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. , 2004, Blood.
[69] N. Chao,et al. Transfer of allogeneic CD 62 L memory T cells without graft-versus-host disease , 2004 .
[70] C. Dinarello,et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[71] S. Riddell,et al. Molecules and mechanisms of the graft-versus-leukaemia effect , 2004, Nature Reviews Cancer.
[72] D. Jain,et al. Donor APCs are required for maximal GVHD but not for GVL , 2004, Nature Medicine.
[73] Harriet Noreen,et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.
[74] D. Jain,et al. Target Antigens Determine Graft-versus-Host Disease Phenotype , 2004, The Journal of Immunology.
[75] J. Cyster,et al. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. , 2005, Annual review of immunology.
[76] E. Podack,et al. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[77] Matthias Edinger,et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. , 2005, Blood.
[78] B. Bierer,et al. Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism1 , 2005, The Journal of Immunology.
[79] J. Ferrara,et al. Critical role of host γδ T cells in experimental acute graft-versus-host disease , 2005 .
[80] J. Ferrara,et al. Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. , 2005, Blood.
[81] J. Berzofsky,et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells , 2005, Nature Medicine.
[82] J. Serody,et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.
[83] M. V. D. van den Brink,et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. , 2005, Blood.
[84] J. Serody,et al. Leukocyte migration and graft-versus-host disease. , 2005, Blood.
[85] R. Korngold,et al. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses , 2005, Nature Medicine.
[86] Katsuaki Sato,et al. TRAIL-Transduced Dendritic Cells Protect Mice from Acute Graft-versus-Host Disease and Leukemia Relapse1 , 2005, The Journal of Immunology.
[87] Jiang Zhu,et al. Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.
[88] D. Pellicci,et al. NKT cell-dependent leukemia eradication following stem cell mobilization with potent G-CSF analogs. , 2005, The Journal of clinical investigation.
[89] K. Kintner,et al. IL-12-Independent LIGHT Signaling Enhances MHC Class II Disparate CD4+ T Cell Alloproliferation, IFN-γ Responses, and Intestinal Graft-versus-Host Disease1 , 2005, The Journal of Immunology.
[90] B. Blazar,et al. Regulatory T cells. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[91] Jiang Zhu,et al. Host-reactive CD8+ memory stem cells in graft-versus-host disease , 2005, Nature Medicine.
[92] G. Hill,et al. Cytokine Expanded Myeloid Precursors Function as Regulatory Antigen-Presenting Cells and Promote Tolerance through IL-10-Producing Regulatory T Cells1 , 2005, The Journal of Immunology.
[93] F. Claas,et al. A Uniform Genomic Minor Histocompatibility Antigen Typing Methodology and Database Designed to Facilitate Clinical Applications , 2006, PloS one.
[94] M. Malkki,et al. Genetics of risk factors for graft-versus-host disease. , 2006, Seminars in hematology.
[95] G. Rogler,et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. , 2006, Blood.
[96] O. Boyer,et al. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. , 2006, Current Opinion in Immunology.
[97] Y. Toda,et al. Ex vivo rapamycin generates Th1/Tc1 or Th2/Tc2 Effector T cells with enhanced in vivo function and differential sensitivity to post-transplant rapamycin therapy. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[98] M. V. D. van den Brink,et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. , 2006, Blood.
[99] Catherine J. Wu,et al. Induction of tumor immunity following allogeneic stem cell transplantation. , 2006, Advances in immunology.
[100] R. Bronson,et al. Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[101] R. Sackstein. A revision of Billingham's tenets: the central role of lymphocyte migration in acute graft-versus-host disease. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[102] E. Holler,et al. Isolation of CD4+CD25+ regulatory T cells for clinical trials. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[103] Christopher H Contag,et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. , 2006, Blood.
[104] T. Banović,et al. Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation. , 2006, Blood.
[105] D. Harlan,et al. T cell–directed therapies: lessons learned and future prospects , 2007, Nature Immunology.
[106] A. Rudensky,et al. Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.
[107] T. George,et al. Naive and Memory T Cells Induce Different Types of Graft-versus-Host Disease1 , 2007, The Journal of Immunology.
[108] G. Zhu,et al. treatment of graft-versus-host disease Selective targeting of the LIGHT-HVEM costimulatory system , 2006 .
[109] W. Murphy,et al. Immunobiology of allogeneic hematopoietic stem cell transplantation. , 2007, Annual review of immunology.
[110] Ruy M Ribeiro,et al. Determining thymic output quantitatively: using models to interpret experimental T‐cell receptor excision circle (TREC) data , 2007, Immunological reviews.
[111] Asha B. Pillai,et al. Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation1 , 2007, The Journal of Immunology.
[112] W. Shlomchik,et al. Graft-versus-host disease , 2007, Nature Reviews Immunology.
[113] S. McColl,et al. IFNgamma differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract. , 2007, Blood.
[114] Vincent C. Manganiello,et al. Foxp3-dependent programme of regulatory T-cell differentiation , 2007, Nature.
[115] A. Rudensky,et al. Thymic development and peripheral homeostasis of regulatory T cells. , 2007, Current opinion in immunology.
[116] J. Wagner,et al. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. , 2006, Blood.
[117] R. Medzhitov. Recognition of microorganisms and activation of the immune response , 2007, Nature.
[118] A. McKenzie,et al. Combined Th2 cytokine deficiency in donor T cells aggravates experimental acute graft-vs-host disease. , 2008, Experimental hematology.
[119] E. Butcher,et al. CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease , 2008, Nature Immunology.
[120] R. Negrin,et al. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. , 2008, Blood.
[121] D. Jain,et al. Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells. , 2008, Blood.
[122] J. Serody,et al. The biology and therapeutic potential of natural regulatory T-cells in the bone marrow transplant setting , 2008, Leukemia & lymphoma.
[123] S. Akira,et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. , 2008, Blood.
[124] R. Korngold,et al. Overlap between in vitro donor antihost and in vivo posttransplantation TCR Vbeta use: a new paradigm for designer allogeneic blood and marrow transplantation. , 2008, Blood.
[125] F. Fallah-Arani,et al. The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells1 , 2008, The Journal of Immunology.
[126] M. Bachmann,et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. , 2008, Blood.
[127] D. Jain,et al. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. , 2008, Blood.
[128] G. Holländer,et al. The immunopathology of thymic GVHD , 2008, Seminars in Immunopathology.
[129] C. Contag,et al. Prevention of acute graft-versus-host disease by blocking T-cell entry to secondary lymphoid organs. , 2008, Blood.
[130] T. Yi,et al. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. , 2008, Blood.
[131] C. Dinarello,et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. , 2008, The Journal of clinical investigation.
[132] Christopher G. King,et al. IL-17 contributes to CD4-mediated graft-versus-host disease. , 2009, Blood.
[133] A. Toubert,et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. , 2009, Blood.
[134] A. Palkova,et al. Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.
[135] Asha B. Pillai,et al. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease. , 2009, Blood.
[136] M. Hessner,et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. , 2009, Blood.
[137] C. Münz. Enhancing immunity through autophagy. , 2009, Annual review of immunology.
[138] Yang Liu,et al. CD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses , 2009, Science.
[139] Michelle L. West,et al. In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. , 2009, Blood.
[140] M. Smyth,et al. Induction of natural killer T cell–dependent alloreactivity by administration of granulocyte colony–stimulating factor after bone marrow transplantation , 2009, Nature Medicine.
[141] R. Porcher,et al. Influence of bone marrow graft B lymphocyte subsets on outcome after HLA‐identical sibling transplants , 2009, British journal of haematology.
[142] X. Li,et al. Costimulatory pathways in transplantation: challenges and new developments , 2009, Immunological reviews.
[143] F. Ginhoux,et al. Differential rates of replacement of human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation , 2009, The Journal of experimental medicine.
[144] C. Dinarello,et al. Cutting Edge: Negative Regulation of Dendritic Cells through Acetylation of the Nonhistone Protein STAT-31 , 2009, The Journal of Immunology.
[145] J. Ritz,et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[146] K. Akashi,et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells. , 2009, Blood.
[147] M. Degli-Esposti,et al. Graft-versus-Host Disease Prevents the Maturation of Plasmacytoid Dendritic Cells1 , 2009, The Journal of Immunology.
[148] G. Besra,et al. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration. , 2009, Blood.